Zentalis Pharmaceuticals, Inc.

ZNTL

US98943L1070

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 17/07/2024 am IST			5-day change	1st Jan Change
4.57 ^USD	+14.82%		+8.04%	-69.83%

01/07	Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell Small Cap Comp Value Index	CI
01/07	Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell 3000 Value Index	CI

Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell Small Cap Comp Value Index

July 01, 2024

Latest news about Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell Small Cap Comp Value Index	01/07	CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell 3000 Value Index	01/07	CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell 2500 Value Index	01/07	CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) dropped from Russell 3000 Growth Index	01/07	CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell 2000 Value Index	01/07	CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) dropped from Russell 3000E Growth Index	01/07	CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) dropped from Russell 2000 Growth Index	01/07	CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) dropped from Russell 2500 Growth Index	01/07	CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) dropped from Russell Small Cap Comp Growth Index	01/07	CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell 3000E Value Index	01/07	CI
UBS Downgrades Zentalis Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $5 From $28	20/06	MT
US Equity Markets Close Up Tuesday Following Less-Than-Expected Retail Sales Growth	19/06	MT
Sector Update: Health Care Stocks Edge Up Late Afternoon	19/06	MT
Sector Update: Health Care	19/06	MT
Jefferies Downgrades Zentalis Pharmaceuticals to Hold From Buy, Cuts Price Target to $6 From $42; Shares Plummet	19/06	MT
Top Midday Decliners	18/06	MT
Morgan Stanley Downgrades Zentalis Pharmaceuticals to Equalweight From Overweight, Cuts PT to $8 From $38; Shares Plunge	18/06	MT
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $10 From $32, Maintains Buy Rating	18/06	MT
Wedbush Downgrades Zentalis Pharmaceuticals to Underperform From Neutral, Cuts Price Target to $4 From $15	18/06	MT
Wells Fargo Downgrades Zentalis Pharmaceuticals to Equal Weight From Overweight, Lowers Price Target to $9 From $29	18/06	MT
Zentalis Pharmaceuticals Shares Fall After FDA Places Partial Clinical Hold on Three Studies	18/06	MT
Traders Digest Retail Sales Data Ahead of Holiday Break, Driving Muted Premarket Action for US Equity Futures	18/06	MT
Zentalis Pharmaceuticals Shares Slide on Partial Clinical Holds on Cancer Drug Studies	18/06	DJ
Transcript : Zentalis Pharmaceuticals, Inc. - Special Call	18/06
US FDA puts partial clinical hold on Zentalis' cancer drug studies; shares drop	18/06	RE

Chart Zentalis Pharmaceuticals, Inc.

Duration

Period

More charts

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Companyâs lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.57 USD

Average target price

10.7 USD

Spread / Average Target

+134.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ZENTALIS PHARMACEUTICALS, INC.	-69.83%	325M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	126B
REGENERON PHARMACEUTICALS, INC.	+24.67%	118B
ARGENX SE	+25.07%	27.87B
BIONTECH SE	-17.74%	20.95B
GENMAB A/S	-15.57%	16.92B
BEIGENE, LTD.	-15.21%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.08B

Bio Therapeutic Drugs